DelveInsight’s Tendinopathy Market Insights report includes a comprehensive understanding of current treatment practices, tendinopathy emerging drugs, market share of individual therapies, and current and forecasted tendinopathy market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

 

Key Takeaways from the Tendinopathy Market Report

• As per DelveInsight’s analysis, the tendinopathy market is anticipated to grow at a significant CAGR by 2032.
• According to DelveInsight’s analysis, tendinopathy incidence in the United States has shown an increasing trend. As per the estimates, the United States accounted for ~12 million incident cases in 2022.
• Leading tendinopathy companies such as Novartis, SynOx Therapeutics Limited, Abbisko Therapeutics Co, Ltd, AmMax Bio, Inc., Deciphera Pharmaceuticals LLC, and others are developing novel tendinopathy drugs that can be available in the tendinopathy market in the coming years.
• Some of the key therapies for tendinopathy treatment include NGI226, Emactuzumab, ABSK021, AMB-05X, DCC-3014, AIN457, and others.

 

Discover which therapies are expected to grab the tendinopathy market share @ Tendinopathy Market Report

 

Tendinopathy Overview

Tendinopathy represents a compromised healing process within the tendon, marked by the chaotic growth of tenocytes, irregularities within tenocyte cells, the disruption of collagen fibers, and a subsequent rise in the non-collagenous matrix. Tendinopathy is a broad term used to describe clinical conditions associated with overuse in and around tendons, encompassing both pain and pathological characteristics.

 

Tendinopathy Epidemiology Segmentation

• Total Incident Cases of Tendinopathy
• Gender-specific Incident Cases of Tendinopathy
• Type-specific Incident Cases of Tendinopathy
• Region-specific Incident Cases of Tendinopathy
• Total Treated Cases of Tendinopathy

 

Download the report to understand which factors are driving tendinopathy epidemiology trends @ Tendinopathy Epidemiological Insights

 

Tendinopathy Treatment Market 

The primary objectives of tendinopathy treatment involve alleviating symptoms, particularly pain, facilitating tendon recovery, and enhancing patient functionality. A variety of therapeutic options are available, such as rest, cold therapy, eccentric exercises, nutraceuticals, ultrasound therapy, sclerosing injections, extracorporeal shockwave therapy, splinting, taping, cryotherapy, electrotherapy, glyceryl trinitrate patches, nonsteroidal anti-inflammatory drugs (NSAIDs), and peritendinous injections. Surgical intervention is typically considered a last resort for persistent tendinopathy cases after exploring all non-operative alternatives. Nevertheless, conservative measures remain the cornerstone of treatment for most tendinopathies.

 

Learn more about the FDA-approved drugs for tendinopathy @ Drugs for Tendinopathy Treatment

 

Key Tendinopathy Therapies and Companies

• NGI226: Novartis
• Emactuzumab: SynOx Therapeutics Limited
• ABSK021: Abbisko Therapeutics Co, Ltd
• AMB-05X: AmMax Bio, Inc.
• DCC-3014: Deciphera Pharmaceuticals LLC
• AIN457: Novartis

 

To know more about tendinopathy clinical trials, visit @ Tendinopathy Drugs

 

Tendinopathy Market Dynamics

The tendinopathy market dynamics are anticipated to change in the coming years. Preclinical models have given credence to this emerging therapeutic modality, and compared to scaffolds and growth factors, there is a paucity of clinical studies using stem cells for augmentation of tendon repair or for treating tendinopathy. Gene therapy is a promising method for facilitating the trafficking of growth factors to the injured site, potentially allowing sustained temporal delivery, while novel mini-invasive procedures that target underlying pathology, such as abnormal neoinnervation, are being developed and are initially promising.

 

Scope of the Tendinopathy Market Report

• Tendinopathy Therapeutic Assessment: Tendinopathy current marketed and emerging therapies
• Tendinopathy Market Dynamics: Attribute Analysis of Emerging Tendinopathy Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Tendinopathy Market Access and Reimbursement

 

Discover more about Tendinopathy drugs in development @ Tendinopathy Clinical Trials

 

Table of Contents

1. Key Insights

2. Executive Summary of Tendinopathy

3. Competitive Intelligence Analysis for Tendinopathy

4. Tendinopathy: Market Overview at a Glance

5. Tendinopathy: Disease Background and Overview

6. Patient Journey

7. Tendinopathy Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Tendinopathy Unmet Needs

10. Key Endpoints of Tendinopathy Treatment

11. Tendinopathy Marketed Products

12. Tendinopathy Emerging Therapies

13. Tendinopathy: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Tendinopathy

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services